AstraZeneca takes rheumatoid arthritis drug Fostamatinib into Ph III trials
AstraZeneca has started the Phase III trials program for fostamatinib disodium (R788), a novel drug for rheumatoid arthritis licensed earlier this year from Rigel Pharmaceuticals.
Fostamatinib is a member of a new class of rheumatoid arthritis drugs called syk kinase inhibitors, and will be tested in three Phase III trials collectively known as the OSKIRA program. AstraZeneca said it hoped to be in a position to file for approval of the drug in 2013.
While there have been a good number of new treatments for rheumatoid arthritis launched in recent years, many of the most successful are biologics, such as the anti-TNF antibodies, and have to be given by injection or infusion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze